Benedict‐Tilman Berger

Author

Also Known As

B.-T. Berger, B.T. Berger, Benedict Tilman Berger, Benedict-Tilman Berger, Benedict-Tilmann Berger, Benedict‐Tilman Berger, Berger, Benedict-Tilman

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Goethe University Frankfurt Heidelberg University German Cancer Research Center Frankfurt Cancer Institute University of Tübingen

About

Benedict‐Tilman Berger is an author at Goethe University Frankfurt specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	795
2	Natural Sciences	8	8	326
3	Biochemistry	7	7	329
4	Engineering	2	2	122
5	Health Sciences	1	1	43

Benedict‐Tilman Berger

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement James D. Vasta, Cesear Corona, Jennifer Wilkinson, Cell chemical biology Drug TargetWide-spectrum Kinase ProfilingKinase InhibitorsCytoskeletonCellular Physiology	2017	281
Binding Kinetics Survey of the Drugged Kinome Victoria Georgi, Felix Schiele, Benedict‐Tilman Berger, Journal of the American Chemical Society Biophysical ModelingDrug TargetEngineeringKinetics InformationSystems Pharmacology	2018	82
CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1 Milan Hluchý, Pavla Gajdušková, Igor Ruiz de los Mozos, Nature Transcriptional RegulationPre-mrna SplicingRna SplicingGene ExpressionMedicine	2022	82
Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2 Benedict‐Tilman Berger, Marta Amaral, Daria B. Kokh, Cell chemical biology Structure-kinetic RelationshipBiochemistryMedicineNatural SciencesReceptor Tyrosine Kinase	2021	77
Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors Maria Reinecke, P. Brear, Larsen Vornholz, Nature Chemical Biology	2023	69
SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK) Christopher R. M. Asquith, Benedict‐Tilman Berger, Jing Wan, Journal of Medicinal Chemistry Collateral TargetMolecular BiologyCell CycleCellular PhysiologySignaling Pathway	2019	68
Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance Agatha Lyczek, Benedict‐Tilman Berger, Aziz M. Rangwala, Proceedings of the National Academy of Sciences	2021	66
Development, Optimization, and Structure–Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine Scaffold Michael Förster, A. Chaikuad, Teodor Dimitrov, Journal of Medicinal Chemistry	2018	58
Furo[3,2‐<i>b</i>]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway Václav Němec, Michaela Hylsová, Lukáš Maier, Angewandte Chemie International Edition	2018	55
Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor Andreas Krämer, Christian Georg Kurz, Benedict‐Tilman Berger, European Journal of Medicinal Chemistry Medicinal ChemistrySelective CaseinDrug TargetBiochemistryMedicine	2020	55

Page 1